Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01221766 · ClinicalTrials.gov registry record

Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease

A clinical trial of Graft Vs Host Disease and Chronic Graft vs. Host Disease, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
12
Enrollment target
2
Study locations

NCT01221766: Completed study of Graft Vs Host Disease and Chronic Graft vs. Host Disease, sponsored by Dana-Farber Cancer Institute.

NCT01221766 is a study of Graft Vs Host Disease and Chronic Graft vs. Host Disease that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants, below the 138-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01221766, a study of Graft Vs Host Disease and Chronic Graft vs. Host Disease, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
12 participants
Enrollment target
2
Study locations

Study Summary

This research study will help us learn more about how chronic graft-versus-host disease affects the skin, hair and nails. We are interested in knowing if hair and nail problems predict worse disease. This information may help us treat patients like you in the future.

Primary Outcome

To determine if adnexal involvement predicts worse severity and/or prognosis in chronic GVHD. This will be measured by administration of systemic therapy other than steroids.

Study Locations (2)

Massachusetts

  • Children's Hospital Boston - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2010-09
Est. Completion 2014-10
Dana-Farber Cancer Institute

781 total trials

What the finished NCT01221766 record still lists

NCT01221766 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 138-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (91% lower).

The record links to 3 conditions, with Graft Vs Host Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01221766 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01221766 about?

NCT01221766 is a clinical study titled "Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease". This research study will help us learn more about how chronic graft-versus-host disease affects the skin, hair and nails. We are interested in knowing if hair and nail problems predict worse disease. This information may help us treat patients like you in the future.

What is the current status of trial NCT01221766?

This trial is currently completed. The enrollment target is 12 participants. The study started on 2010-09. Estimated completion is 2014-10.

What conditions does trial NCT01221766 study?

This clinical trial studies the following conditions: Graft Vs Host Disease, Chronic Graft vs. Host Disease, cGVHD.

Who is sponsoring clinical trial NCT01221766?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01221766 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Graft Vs Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01221766's enrollment target sits among peer trials

12 35th of 36 higher than 2 of 36 other Graft Vs Host Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Graft Vs Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01221766, the US trial registry maintained by the National Library of Medicine. NCT01221766 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.